2 Azacitidine Scams And A Way To Defend Against Them

Dosimetry based method aims at achieving high rates of cure and euthyroidism, but these methods cause higher utilization of resources.[13] Empirical method is simple and includes administration of a fixed dose of 131I. However, empirical dose, which needs to be administered to achieve high cure rates, has remained a constant Azacitidine matter of debate. Many studies addressing this topic have shown that empirical therapy is not inferior to dosimetry based therapy and higher dose (370 MBq) is associated with higher cure rates than lower doses (185 MBq).[14,15,16] Moreover, aim of treatment of Grave's disease is to achieve either euthyroidism or hypothyroidism and so treatment with higher doses remains a logical choice with acceptable higher risk of hypothyroidism.[17] However, even with higher doses of up to 370 MBq dose a fraction of patients do not respond to a single dose of therapy.[9] Our study was aimed to identify the factors associated with treatment failure with higher dose of 131I and thus lead to further studies aimed at increasing dose still higher to increase cure rates. In this study, all the patients received a higher dose of 259-370 MBq (mean dose of 305 MBq). Twenty-five (16.6%) patients had to be retreated within a year and complete remission Galunisertib was achieved in 125 patients, and cure rate was (83.4%). This is higher than complete remission rates achieved with a lower dose (around 185 MBq) and consistent with studies reporting higher success rates with higher dose of 131I.[9,14] In our study, male sex was associated with increased failure rates and is in concordance with previous studies.[9] Few earlier studies have reported that patients with large goiters have poor response rates,[18] however in our study, large goiter was not predictor of treatment failure. This might be due to the fact that in our study goiter was graded visually according to new WHO classification[19] and also no quantification of the volume was done. Quantification of thyroid volume by USG or other modalities would have probably revealed the significance of thyroid volume in predicting the treatment failure. Other parameters considered like age, duration of disease, mean dose or duration of methimazole used did not predict treatment failure in our study. Importantly intake of anti-thyroid drugs did not Arginase influence the outcome in our study, which might be due to the higher dose of 131I used as well as due the fact that anti-thyroid drugs were stopped 7 days prior to 131I therapy, which decreases the incidence of treatment failure.[20,21] 99mTcO4- uptake at 20 min showed significant AUC with ROC curve analysis and the cut-off of 17.75% was able to predict treatment failure with sensitivity and specificity of 68% and 66%. Furthermore, patients with 99mTcO4- uptake greater than 17.75% had odds of 3.14; implying 3 times higher risk for treatment failure than patients with uptake